Get started
CHARLES RIVER LABORATORIESCHARLES RIVER LABORATORIESCHARLES RIVER LABORATORIES

CHARLES RIVER LABORATORIES

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

CRL chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats

Market capitalization
‪198.51 B‬MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
27.03
Basic EPS (TTM)
143.57MXN
Net income (FY)
‪8.06 B‬MXN
Revenue (FY)
‪70.14 B‬MXN
Shares float
‪50.46 M‬
Beta (1Y)
1.54

About Charles River Laboratories International, Inc.

Sector
Commercial Services
Industry
Miscellaneous Commercial Services
CEO
James C. Foster
Website
criver.com
Headquarters
Wilmington
Employees (FY)
‪21.8 K‬
Founded
1947
FIGI
BBG013GN0YY2
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of CRL is 4048.97 MXN — it has increased by 1.84% in the past 24 hours. Watch CHARLES RIVER LABORATORIES stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange CHARLES RIVER LABORATORIES stocks are traded under the ticker CRL.
We've gathered analysts' opinions on CHARLES RIVER LABORATORIES future price: according to them, CRL price has a max estimate of 5045.41 MXN and a min estimate of 3800.87 MXN. Watch CRL chart and read a more detailed CHARLES RIVER LABORATORIES stock forecast: see what analysts think of CHARLES RIVER LABORATORIES and suggest that you do with its stocks.
CRL reached its all-time high on Apr 8, 2022 with the price of 6088.87 MXN, and its all-time low was 3249.12 MXN and was reached on Nov 15, 2023. View more price dynamics on CRL chart.
See other stocks reaching their highest and lowest prices.
CRL stock is 2.40% volatile and has beta coefficient of 1.54. Track CHARLES RIVER LABORATORIES stock price on the chart and check out the list of the most volatile stocks — is CHARLES RIVER LABORATORIES there?
Today CHARLES RIVER LABORATORIES has the market capitalization of ‪202.35 B‬, it has increased by 4.37% over the last week.
Yes, you can track CHARLES RIVER LABORATORIES financials in yearly and quarterly reports right on TradingView.
CHARLES RIVER LABORATORIES is going to release the next earnings report on Jul 31, 2024. Keep track of upcoming events with our Earnings Calendar.
CRL earnings for the last quarter are 37.62 MXN per share, whereas the estimation was 34.22 MXN resulting in a 9.93% surprise. The estimated earnings for the next quarter are 40.41 MXN per share. See more details about CHARLES RIVER LABORATORIES earnings.
CHARLES RIVER LABORATORIES revenue for the last quarter amounts to ‪16.76 B‬ MXN despite the estimated figure of ‪16.45 B‬ MXN. In the next quarter revenue is expected to reach ‪17.30 B‬ MXN.
CRL net income for the last quarter is ‪1.21 B‬ MXN, while the quarter before that showed ‪3.18 B‬ MXN of net income which accounts for −61.95% change. Track more CHARLES RIVER LABORATORIES financial stats to get the full picture.
No, CRL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 15, 2024, the company has ‪21.80 K‬ employees. See our rating of the largest employees — is CHARLES RIVER LABORATORIES on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CHARLES RIVER LABORATORIES EBITDA is ‪15.74 B‬ MXN, and current EBITDA margin is 23.62%. See more stats in CHARLES RIVER LABORATORIES financial statements.
Like other stocks, CRL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CHARLES RIVER LABORATORIES stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CHARLES RIVER LABORATORIES technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CHARLES RIVER LABORATORIES stock shows the buy signal. See more of CHARLES RIVER LABORATORIES technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.